Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Aziz Zaanan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8372-5653; OpenAlex author ID A5033663279. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers

Papers 10

  1. Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2024.103975↗
  2. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  3. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Co-author DOI 10.1016/j.ctrv.2020.102028↗
  4. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  5. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Co-author DOI 10.1007/s11136-015-1198-x↗
  6. Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A… Co-author DOI 10.1371/journal.pone.0125350↗
  7. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Co-author DOI 10.1016/j.clinre.2014.01.005↗
  8. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastat… Co-author DOI 10.1016/j.ejca.2014.09.015↗
  9. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. Co-author DOI 10.1186/1471-2407-14-441↗
  10. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Co-author DOI 10.1016/j.clinre.2011.02.002↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julien Taı̈eb · 8 shared papers, 2011–2024 · strength 0.58
  2. Claire Gallois · 1 shared paper, 2024 · strength 0.24
  3. Isabelle Trouilloud · 4 shared papers, 2011–2015 · strength 0.14
  4. Jean‐Baptiste Bachet · 2 shared papers, 2011–2020 · strength 0.14
  5. Franck Bonnetain · 3 shared papers, 2014–2016 · strength 0.13
  6. Raëf Abdallah · 1 shared paper, 2020 · strength 0.11
  7. Léo Mas · 1 shared paper, 2020 · strength 0.11
  8. Shulin Zhao · 1 shared paper, 2020 · strength 0.11
  9. Pierre Laurent‐Puig · 1 shared paper, 2020 · strength 0.11
  10. Daniel Pietrasz · 1 shared paper, 2020 · strength 0.11
  11. Debora Basile · 1 shared paper, 2020 · strength 0.11
  12. David Malka · 2 shared papers, 2014–2016 · strength 0.08
  13. Anne‐Laure Pointet · 1 shared paper, 2016 · strength 0.05
  14. Momar Diouf · 1 shared paper, 2016 · strength 0.05
  15. Amélie Anota · 1 shared paper, 2015 · strength 0.04
  16. Alix Portal · 1 shared paper, 2014 · strength 0.04
  17. Philippe R Rougier · 1 shared paper, 2014 · strength 0.04
  18. Simon Pernot · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.